Home > Insider Trading > Filing (0001127602-12-013329)

Filing Details

Accession Number:: 0001127602-12-013329
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2012-04-04 13:00:00
Reporting Period:: 2012-04-01

Filing Date:: 2012-04-04
Accepted Time:: 2012-04-04 17:03:01
Original Submission Date:: 2012-04-03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1395777	Duane Desisto	C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-04-01	70,000	$0.00	140,497	No	4	A	Direct
Common Stock	Acquisiton	2012-04-02	2,235	$3.60	160,497	No	4	M	Direct
Common Stock	Acquisiton	2012-04-02	17,765	$2.50	158,262	No	4	M	Direct
Common Stock	Disposition	2012-04-02	20,000	$19.35	140,497	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2012-04-01	70,000	$0.00	70,000	$19.14
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-04-02	2,235	$0.00	2,235	$3.60
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-04-02	17,765	$0.00	17,765	$2.50

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,000	2022-04-01	No	4	A	Direct
265,527	2015-02-09	No	4	M	Direct
0	2014-02-23	No	4	M	Direct

Footnotes

This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
This option may be exercised at any time, whether vested or not, but, upon termination of employment, we may repurchase any unvested shares at the exercise price paid for the shares. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal monthly installments each month thereafter for 36 months, subject to continued employment.
The 70,000 restricted stock units vest one-quarter of the total units on the first anniversary date of the grant and one-quarter each on the second, third and fourth anniversaries of the date of the grant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
Includes 13,334 restricted stock units granted on March 1, 2010 which vest on March 1, 2013; and 26,667 restricted stock units granted on March 1, 2011 which vest one-half each on March 1, 2013 and March 1, 2014. Vested shares will be delivered to the reporting person as soon as practiable following a vesting date.
Includes an aggregate of 7,198 shares acquired under the Insulet Corporation 2007 Employee Stock Purchase Plan on the following dates: 219 shares acquired on December 31, 2007; 694 shares acquired on June 30, 2008; 1,429 shares acquired on December 31, 2008; 1,431 shares acquired on June 30, 2009; 772 shares acquired on December 31, 2009; 749 shares acquired on June 30, 2010; 732 shares acquired on December 31, 2010; 532 shares acquired on June 30, 2011; and 640 shares acquired on December 30, 2011.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2011.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $19.055 to $19.64. The reporting Person hereby undertakes, upon request of the Staff of the U.S Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.